Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A)

被引：0
|
作者：
Simpkins, Fiona
Nasioudis, Dimitrios
Wethington, Stephanie L.
Martin, Lainie P.
Tanyi, Janos Laszlo
Latif, Nawar A.
Torigian, Drew A.
Omran, Dalia K.
Rodriguez, Diego
Smith, Simon
Dean, Emma
Domchek, Susan M.
Drapkin, Ronny
Shih, Ie-Ming
Brown, Eric J.
Hwang, Wei-Ting
Armstrong, Deborah Kay
Gaillard, Stephanie
Giuntoli, Robert Lawrence, II
Liu, Joyce F.
机构：
[1] Penn Med Abramson Canc Ctr, Philadelphia, PA USA
[2] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[3] Univ Penn, Dept Radiol, Philadelphia, PA USA
[4] AstraZeneca, R&D Oncol, Royston, England
[5] AstraZeneca, R&D Oncol, Cambridge, England
[6] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Baltimore, MD USA
[7] Univ Penn, Dept Canc Biol, Philadelphia, PA USA
[8] Univ Penn, Abramson Family Canc Res Inst, Perelman Sch Med, Philadelphia, PA USA
[9] Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5510
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Niraparib in Japanese patients with platinum-sensitive recurrent ovarian cancer: final results of a multicenter phase 2 study
    Itamochi, Hiroaki
    Takeshima, Nobuhiro
    Hamanishi, Junzo
    Hasegawa, Kosei
    Matsuura, Motoki
    Miura, Kiyonori
    Nagao, Shoji
    Nakai, Hidekatsu
    Tanaka, Naotake
    Tokunaga, Hideki
    Nishio, Shin
    Watari, Hidemichi
    Yokoyama, Yoshihito
    Kase, Yoichi
    Sumino, Shuuji
    Kato, Ai
    Suri, Ajit
    Yasuoka, Toshiaki
    Takehara, Kazuhiro
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (05)
  • [32] Biomarker correlates from the randomized phase 2 trial of the PARP inhibitor olaparib (O) with or without the antiangiogenic TKI cediranib (C) in recurrent platinum-sensitive ovarian cancer (NCT01116648).
    Lee, Jung-min
    Liu, Joyce
    Choyke, Peter L.
    Elbuluk, Osama
    Turkbey, Ismail B.
    Trepei, Jane B.
    Lee, Min-Jung
    Cao, Liang
    Houston, Nicole D.
    Gordon, Nicolas
    Figg, William Douglas
    Barry, William Thomas
    Matulonis, Ursula
    Birrer, Michael J.
    Ivy, Percy
    Kohn, Elise C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Efficacy of subsequent chemotherapy regimens in platinum-sensitive recurrent ovarian cancer following PARP inhibitor progression: a multicenter retrospective study
    Zhao, Yuxi
    Kang, Haili
    Zhao, Hongwei
    Wang, Li
    Duan, Wei
    Wu, Lingying
    Zuo, Jing
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A76 - A78
  • [34] Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ ENGOT-ov38): a phase IIIb trial
    Pujade-Lauraine, E.
    Selle, F.
    Scambia, G.
    Asselain, B.
    Marme, F.
    Lindemann, K.
    Colombo, N.
    Madryl, R.
    Glasspool, R.
    Vergote, I.
    Korach, J.
    Lheureux, S.
    Dubot, C.
    Oaknin, A.
    Zamagni, C.
    Heitz, F.
    Gladieff, L.
    Rubio-Perez, M. J.
    Scollo, P.
    Blakeley, C.
    Shaw, B.
    Ray-Coquard, I
    Redondo, A.
    ANNALS OF ONCOLOGY, 2023, 34 (12) : 1152 - 1164
  • [35] PARP inhibitors as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: Can we afford it?
    Smith, H. J.
    Haygood, C. L. Walters
    Arend, R. C.
    Leath, C. A., III
    Straughn, J. M., Jr.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 9 - 9
  • [36] A real-world study of PARP inhibitors in 75 patients with platinum-sensitive recurrent ovarian cancer from China
    Chen, Jinghong
    Zhang, Mengpei
    Li, Kemin
    Duan, Yuanqiong
    Lin, Xiaojuan
    Zhong, Lan
    Li, Qintong
    Yin, Rutie
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [37] The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients
    Safra, Tamar
    Asna, Noam
    Veizman, Anat
    Shpigel, Shulem
    Matcejevsky, Dianna
    Inbar, Moshe
    Grisaru, Dan
    ANTI-CANCER DRUGS, 2014, 25 (03) : 340 - 345
  • [38] Phase 2 study of weekly triplet regimen of docetaxel, carboplatin and gemcitabine in recurrent platinum-sensitive epithelial ovarian cancer.
    Salimichokami, M
    Vahid, AA
    Mir, MR
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 486S - 486S
  • [39] A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer
    Case, Ashley S.
    Rocconi, Rodney P.
    Partridge, Edward E.
    Straughn, J. Michael, Jr.
    GYNECOLOGIC ONCOLOGY, 2007, 105 (01) : 223 - 227
  • [40] A phase I study of lapatinib in combination with carboplatin in women with recurrent platinum-sensitive ovarian carcinoma
    Kimball, K. J.
    Numnum, T. M.
    Kirby, T. O.
    Zamboni, W. C.
    Estes, J. M.
    Barnes, M. N.
    Matei, D.
    Alvarez, R. D.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S60 - S60
12345